MBX Biosciences' Phase 3 hypoparathyroidism trial enrolls, obesity pipeline advancesNov 16Clinical readoutcanvuparatideMBX BiosciencesUpdated
MBX Biosciences doses first patient in Phase 3 trial of canvuparatide for hypoparathyroidismAug 27Trial updatecanvuparatideMBX Biosciences
MBX Biosciences reports Q2 2026 results, canvuparatide Phase 3 recruitingAug 6Quarterly updatecanvuparatideMBX Biosciences
MBX Biosciences registers Phase 3 trial of canvuparatide for hypoparathyroidismJul 13Trial updatecanvuparatideMBX Biosciences